Abdullah Sayiner

Abdullah Sayiner

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
NKNurdan Kokturk
Nurdan Kokturk
CBCenk Babayigit
Cenk Babayigit
SKSeval Kul
Seval Kul
PÇPelin Duru Çetinkaya
Pelin Duru Çetinkaya
SNSibel Atis Nayci
Sibel Atis Nayci
HBHasan Bayram
Hasan Bayram

12 March 2014 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DSDave Singh
Dave Singh
GNGabriele Nicolini
Gabriele Nicolini
EBEddi Bindi
Eddi Bindi
Massimo CorradiMassimo Corradi
Massimo Corradi
DGDaniele Guastalla
Daniele Guastalla
JVJørgen Vestbo
Jørgen Vestbo
The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination in COPD patients. The trial was a 12-week multicentre, randomised, double-blind, double dummy study; 419 patients with moderate/severe COPD were randomised to BDP/FF 200/12 μg or FP/S 500/50 μg twice daily. The primary objective was to demonstrate the equivalence between treatments in terms of Transition Dyspnoea Index (TDI) score and the superiority of BDP/FF in terms of change from pre-dose in the first 30 minutes in forced expiratory volume in the first second (FEV1). Secondary endpoints included lung function, symptom scores, symptom-free days and use of rescue medication, St. George’s Respiratory Questionnaire, six minute walking test and COPD exacerbations. BDP/FF was equivalent to FP/S in terms of TDI score and superior in terms of FEV1 change from pre-dose (p < 0.001). There were no significant differences between treatments in secondary outcome measures, confirming overall comparability in terms of efficacy and tolerability. Moreover, a clinically relevant improvement (>4 units) in SGRQ was detected in the BDP/FF group only. BDP/FF extrafine combination provides COPD patients with an equivalent improvement of dyspnoea and a faster bronchodilation in comparison to FP/S. ClinicalTrials.gov: NCT01245569

30 April 2014 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
YCYelda Ceviker
Yelda Ceviker
ASAbdullah Sayiner
Abdullah Sayiner

14 July 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
ECEzgi Demirdogen Cetinoglu
Ezgi Demirdogen Cetinoglu
EUEsra Uzaslan
Esra Uzaslan
ASAbdullah Sayiner
Abdullah Sayiner
ACAykut Cilli
Aykut Cilli
OKOguz Kılınc
Oguz Kılınc
OGon behalf of TURCAP Study Group
on behalf of TURCAP Study Group
Previous reports have shown that vaccination rates of adult at-risk populations are low in Turkey. There are differing reports with regards to the effectiveness of the influenza and the pneumococcal polysaccharide vaccine (PPSV23) on the clinical outcomes of community acquired pneumonia (CAP). The purpose of this study was to analyze the influenza (FV) and pneumococcal vaccination (PV) status, the factors that influence the receipt of influenza/pneumococcal vaccine and the effects of prior vaccination on the clinical outcomes in adults hospitalized with CAP. Patients hospitalized with CAP between March 2009 and October 2013 and registered at the web-based Turkish Thoracic Society Pneumonia Database (TURCAP) were included in this multicentric, observational study. Of a total of 787 cases, data were analyzed for 466 patients for whom self-reported information on PV and FV was available. In this adult population with CAP, the vaccination rate with both the pneumococcal and influenza vaccines was found to be 6%. Prior FV was found to be the sole variable that was associated with the receipt of PV [OR 17.8, 95% CI (25-75:8.56-37.01), p < 0.001]. Conversely, being vaccinated with PPSV23 was the only predictor of receipt of FV [OR 18.1, 95% CI (25 - 75:8.75 - 37.83), p < 0.001]. Compared to the unvaccinated cases, the chest radiograms of the vaccinated patients revealed less consolidation. The latter also reported fatigue, muscle pain and gastrointestinal symptoms less frequently. Although there was a trend for lower 30-day mortality and for lower rates of intensive care unit (ICU) admission, these did not reach statistical significance. A pneumonia severity index (PSI) score ≥ 90, CURB-65 score ≥3 and multilobar involvement, but not the vaccination status, were identified as independent determinants of ICU admission. This study showed that, among patients hospitalized with CAP, the FV and/or PV rates are low. Prior vaccination does not appear to significantly affect the clinical outcomes.

28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
HEHüseyi̇n Aytaç Erdem
Hüseyi̇n Aytaç Erdem
PEPervİn Korkmaz Ekren
Pervİn Korkmaz Ekren
DÇDerya Çağlayan
Derya Çağlayan
MTMeltem Taşbakan
Meltem Taşbakan
TYTansu Yamazhan
Tansu Yamazhan
DGDeniz Gokengin
Deniz Gokengin
The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS CoV-2 pneumonia. This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the ICU when this paper was written. This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.

20 March 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
YKYagmur Kaptan
Yagmur Kaptan
ASAsli Suner
Asli Suner
MTMehmet Nedim Taş
Mehmet Nedim Taş
FOFahrettin Oksel
Fahrettin Oksel
KAKenan Aksu
Kenan Aksu
ASAbdullah Sayiner
Abdullah Sayiner